Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  ZIOPHARM Oncology Inc.    ZIOP

ZIOPHARM ONCOLOGY INC.

(ZIOP)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/15/2019 07/16/2019 07/17/2019 07/18/2019 07/19/2019 Date
5.73(c) 5.75(c) 5.73(c) 5.65(c) 5.48(c) Last
745 809 726 853 917 992 732 776 1 054 029 Volume
+0.35% +0.35% -0.35% -1.40% -3.01% Change
More quotes
Financials (USD)
Sales 2019 3,64 M
EBIT 2019 -54,5 M
Net income 2019 -53,7 M
Debt 2019 -
Yield 2019 -
Sales 2020 1,60 M
EBIT 2020 -57,2 M
Net income 2020 -56,8 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -17,3x
P/E ratio 2020 -22,5x
Capi. / Sales2019 240x
Capi. / Sales2020 548x
Capitalization 875 M
More Financials
Company
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene... 
More about the company
Surperformance© ratings of ZIOPHARM Oncology Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on ZIOPHARM ONCOLOGY INC.
07/04ZIOPHARM ONCOLOGY : Names NCI's Dr. Drew Deniger to Direct TCR-T Cell Therapy Pr..
AQ
07/03ZIOPHARM ONCOLOGY INC : Regulation FD Disclosure, Financial Statements and Exhib..
AQ
07/03Ziopharm Oncology Names NCI's Dr. Drew Deniger to Direct TCR-T Cell Therapy ..
GL
06/27Ziopharm Oncology Initiates Phase 2 Trial Evaluating Combination Therapy of C..
GL
06/27ZIOPHARM ONCOLOGY : Completes Enrollment of Controlled IL-12 plus Opdivo Phase 1..
AQ
06/27ZIOPHARM ONCOLOGY : Completes Enrollment of Controlled IL-12 plus Opdivo (nivolu..
AQ
06/26ZIOPHARM ONCOLOGY INC : Regulation FD Disclosure, Financial Statements and Exhib..
AQ
06/26Ziopharm Oncology Completes Enrollment of Controlled IL-12 plus Opdivo® (nivo..
GL
06/17ZIOPHARM ONCOLOGY INC : Change in Directors or Principal Officers, Submission of..
AQ
06/17Ziopharm Oncology Appoints Heidi Hagen to Board of Directors
GL
More news
Analyst Recommendations on ZIOPHARM ONCOLOGY INC.
More recommendations
Sector news : Bio Therapeutic Drugs

- No features available -

More sector news : Bio Therapeutic Drugs
Chart ZIOPHARM ONCOLOGY INC.
Duration : Period :
ZIOPHARM Oncology Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZIOPHARM ONCOLOGY INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 5,75  $
Last Close Price 5,48  $
Spread / Highest target 36,9%
Spread / Average Target 4,93%
Spread / Lowest Target -45,3%
EPS Revisions
Managers
NameTitle
Laurence James Neil Cooper Chief Executive Officer & Director
David M. Mauney President
Kevin G. Lafond Treasurer, Chief Accounting Officer & SVP-Finance
James Anthony Cannon Independent Director
Scott L. Tarriff Lead Director
Sector and Competitors
1st jan.Capitalization (M$)
ZIOPHARM ONCOLOGY INC.193.05%0
GILEAD SCIENCES3.98%85 461
VERTEX PHARMACEUTICALS7.47%45 613
REGENERON PHARMACEUTICALS-20.18%33 087
GENMAB14.94%11 905
SAREPTA THERAPEUTICS INC38.94%11 244